GameSquad for Adults With Down Syndrome

Sponsor
University of Kansas Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05473247
Collaborator
HRSA/Maternal and Child Health Bureau (U.S. Fed)
30
1
95.9

Study Details

Study Description

Brief Summary

The investigators are assessing acceptability, appropriateness, and feasibility of the adapted GameSquad-DS intervention using validated scales alongside qualitative data among young adults with Down Syndrome. Specifically, the investigators will assess mins/wk of Ring-Fit Adventure played, attendance at 30 min. virtual health coaching sessions, semi-structured interviews, participant retention, and intervention safety measured as number of adverse events.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Ring-Fit Adventure Group
N/A

Detailed Description

Adults with DS face unique barriers to participation in MVPA. Exergames, which integrate MVPA into video game play are an affordable, accessible, home-based exercise program which has shown effectiveness for increasing MVPA and improving both physical and cognitive function in typically developed populations. An exergaming intervention with individual health coaching called GameSquad has been shown to be effective in improving MVPA and cardiometabolic parameters in children with overweight/obesity and adolescents with neurodevelopmental and psychiatric diagnoses. The investigators propose a two phased project to adapt/evaluate the GameSquad intervention for use in adults with DS (GameSquad-DS). In Phase 1, the investigators will utilize a formative approach to develop GameSquad-DS, pilot test the intervention for 4 weeks in 10 young adults with DS and use feedback to refine the intervention for use in Phase 2. In Phase 2, the investigators will conduct a 12-wk. single arm pilot trial in 20 young adults with DS to assess the acceptability, appropriateness, and feasibility of the intervention and calculate effect sizes for change MVPA, physical function, muscular strength, physical activity enjoyment, and self-efficacy. Successful completion of this project represents an initial step in achieving the goal of developing effective interventions to increase MVPA and promote healthy aging in adults with DS.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Adaption of the GameSquad Exergaming Intervention for Young Adults With Down Syndrome: A Pilot Feasibility Study
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Aug 30, 2030

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ring-Fit Adventure Group

In Phase 1, participants will be asked to play Ring-Fit Adventure for 60 minutes per week for 4 weeks. Participants will also be asked to attend a weekly, 90 minute health education session with a health educator on zoom. In Phase 2, participants will be asked to play Ring-Fit Adventure for 60 (wk 1), 90 (wk 2), 120 (wk 3), and 150 (wk 4-12) minutes per week. Participants will also be asked to attend a weekly, 90 minute health education session with a health educator on zoom.

Behavioral: Ring-Fit Adventure Group
Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.

Outcome Measures

Primary Outcome Measures

  1. Minutes of Gameplay per week [12-weeks]

    Minutes of Ring-Fit Adventure played per week will be collected from a self-reported sign in sheet.

  2. Retention [12-weeks]

    Participant retention will be collected.

  3. Attendance [12-weeks]

    Attendance at 30 min virtual health coaching sessions will be collected.

Secondary Outcome Measures

  1. 6-minute walk test [12-weeks]

    This test measures the distance that a participant can walk on a flat, hard surface in a period of 6 minutes. The research team will instruct them on how to prepare and conduct this test.

  2. Leg Strength [12-weeks]

    Leg strength will be measured on the leg press machine. Researchers will assess the maximum amount of weight the participant can press for 5 repetitions.

  3. Hand Grip Strength [12-weeks]

    The participant will be asked to squeeze a device as hard as they can to test their grip strength. This will be done on both hands.

  4. Timed Up and Go [12-weeks]

    During this test, the participant will be asked to sit down in a chair. Approximately 10 feet in front of the participant there will be a line on the floor. The research team will say "go" and the participant will get up from the chair, walk to the line at a normal pace, and then turnaround and walk back to the chair and sit down again. The research team will record how long it takes to do this.

  5. Balance [12-weeks]

    During this test, the investigators will ask the participant to balance on one leg and reach in three directions as far as they can with their other foot. They will then do the same on the other leg.

  6. Adverse Events [12-weeks]

    Adverse events will be collected.

  7. Qualitative Interview Data [12-weeks]

    Semi-Structured interviews will occur after the 12-week intervention to allow participants to make sense of their experience in the intervention.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Young adults (18-30 yrs.).

  • Diagnosis of DS.

  • Sufficient functional ability to understand directions, communicate preferences, wants, and needs through spoken language.

  • Living at home with a parent/guardian or in a supported living environment with a parent/caregiver who agrees to serve as a study partner.

Exclusion Criteria:
  • Unable to participate in MVPA.

  • Serious medical risk, e.g., cancer, recent heart attack, stroke, angioplasty as determined by their primary care provider (PCP).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Kansas Medical Center
  • HRSA/Maternal and Child Health Bureau

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kameron Suire, Postdoctoral Researcher, University of Kansas Medical Center
ClinicalTrials.gov Identifier:
NCT05473247
Other Study ID Numbers:
  • STUDY00148828
First Posted:
Jul 25, 2022
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2022